Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery

NewsGuard 100/100 Score
May 3 2010

Omeros Corporation (Nasdaq: OMER) today announced additional data from a Phase 2 trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, showing that patients treated with OMS103HP during arthroscopic meniscectomy surgery achieved statistically significant clinical benefits. OMS103HP is an investigational drug product that is added to arthroscopic irrigation solution and is designed to improve postoperative joint function and motion and reduce postoperative pain. Omeros plans to present these additional data tomorrow in its webcast presentation at the Deutsche Bank Health Care Conference at 2:50 p.m. EDT and, for those not attending, has provided the clinical trial results below.

SOURCE Omeros Corporation

Posted in: Drug Trial News | Medical Procedure News | Medical Condition News

Tags: , , , , , , , , , , ,

Comments (0)

Suggested Reading

Delirium linked to tripled dementia risk in older adults, Australian study finds
Bariatric surgery outperforms traditional treatments for long-term diabetes control
Breakthrough obesity treatments on the horizon, rivaling surgery's success
Google Gemini and Bard pass the ophthalmology board examination
Study links symptomatic dizziness to higher mortality risk
Study reveals key gut microbiome differences in prediabetic patients
Gastric bypass shows slight edge over sleeve gastrectomy in long-term study
What does the future hold for obesity medication development?

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Smoking, drinking, and dietary habits linked to head and neck cancer risk, study finds